Get started
Author

Izumi Nishino

Observed name: Nishino, Izumi
Observed institution: Taisho Pharmaceutical (Japan)
ORCID: 0000-0002-7754-1986
Observed ORCID: 0000-0002-7754-1986
OpenAlex ID: A5038520400
Efficacy and safety of TS-121, a novel vasopressin V1B receptor antagonist, as adjunctive treatment for patients with major depressive disorder: A randomized, double-blind, placebo-controlled study
2020 · Makoto Kamiya, Helene D. Sabia, et al. · Journal of Psychiatric Research · 28
PDF
Validity and reliability of a driving simulator for evaluating the influence of medicinal drugs on driving performance
2020 · Mari Iwata, Kunihiro Iwamoto, et al. · Psychopharmacology · 16
Optimal dose determination of enerisant (TS-091) for patients with narcolepsy: two randomized, double-blind, placebo-controlled trials
2022 · Yuichi Inoue, Makoto Uchiyama, et al. · BMC Psychiatry · 11
Using the drug repositioning approach to develop a novel therapy, tipepidine hibenzate sustained-release tablet (TS-141), for children and adolescents with attention-deficit/hyperactivity disorder
2020 · Takuya Saito, Yushiro Yamashita, et al. · BMC Psychiatry · 11
PDF
Imaging Pituitary Vasopressin 1B Receptor in Humans with the PET Radiotracer 11C-TASP699
2021 · Mika Naganawa, Nabeel B. Nabulsi, et al. · Journal of Nuclear Medicine · 10
Pharmacokinetic and pharmacodynamic assessment of histamine H3 receptor occupancy by enerisant: a human PET study with a novel H3 binding ligand, [11C]TASP457
2021 · Yasuyuki Kimura, Keisuke Takahata, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 7
Drug–drug interaction potential and clinical pharmacokinetics of enerisant, a novel potent and selective histamine H3 receptor antagonist
2021 · Shuichi Terasaka, Kenji Hachiuma, et al. · Xenobiotica · 7
PDF
Prediction of a clinically effective dose of THY1773, a novel V1Breceptor antagonist, based on preclinical data
2021 · Shoko Inatani, Akiko Mizuno‐Yasuhira, et al. · Biopharmaceutics & Drug Disposition · 7
PDF
Drug–drug interaction potential and clinical pharmacokinetics of enerisant, a novel potent and selective histamine H3 receptor antagonist
2021 · Terasaka, Shuichi, Hachiuma, Kenji, et al. · Figshare
Works count: 13
Citation count: 97
H-index: 7
I10-index: 5
Year
Topic
Type